Naslov
Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study

Autori
Khunti, K. ; Alsifri, S. ; Aronson, R. ; Cigrovski Berković, M. ; Enters-Weijnen, C. ; Forsén, T. ; Galstyan, G. ; Geelhoed-Duijvestijn, P. ; Goldfracht, M. ; Gydesen, H. ; Kapur, R. ; Lalic, N. ; Ludvik, B. ; Moberg, E. ; Pedersen-Bjergaard, U. ; Ramachandran, A. ; on behalf of the HAT Investigator Group

Izvornik
Diabetes, Obesity and Metabolism (1462-8902) 18 (2016), 9; 907-915

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Adriatic ; Insulin glargine ; Premixed insulin ; Type 2 diabetes mellitus

Sažetak
AIMS: Type 2 diabetes mellitus (T2DM) is a progressive disease, often requiring exogenous insulin therapy and treatment intensification. Despite new therapies, most patients do not reach the recommended HbA1c targets, among them a significant proportion of patients on premixed insulins. The aim was to summarize published data in Adriatic countries on effectiveness of insulin glargine based therapy in type 2 diabetic patients suboptimally controlled on premix insulin. METHODS: A meta-analysis was carried out in major medical databases up to April 2014, focusing on Adriatic region. We searched observational studies with duration of at least 6 months, evaluating effectiveness and safety of insulin glargine (IGlar), in combination with OAD or bolus insulin in patients with T2 failing premixed insulin therapy. Outcomes included values of HbA1c, fasting blood glucose and two hours post-prandial glucose concentration as well as changes in body mass index after at least 6 months of study duration. RESULTS: Three prospective, observational, multicentric trials (698 patients in total) were included. The basal bolus regimen with glargine significantly reduced HbA1c (Mean Difference, MD=2.27, CI [1.76, 2.78]), fasting glucose (MD=5.15, CI [4.86, 5.44]) and 2-hours postprandial glucose concentration (MD=6.94, CI [6.53, 7.34]). No significant changes were found in BMI after switching from premixes to IGlar based treatment. CONCLUSION: Insulin glargine based therapy following premix failure is efficacious and safe option of type 2 diabetes treatment intensification.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA